WO2008102563A1 - 血管攣縮の治療剤又は予防剤 - Google Patents

血管攣縮の治療剤又は予防剤 Download PDF

Info

Publication number
WO2008102563A1
WO2008102563A1 PCT/JP2008/000306 JP2008000306W WO2008102563A1 WO 2008102563 A1 WO2008102563 A1 WO 2008102563A1 JP 2008000306 W JP2008000306 W JP 2008000306W WO 2008102563 A1 WO2008102563 A1 WO 2008102563A1
Authority
WO
WIPO (PCT)
Prior art keywords
vasoconstriction
therapeutic
prophylactic agent
cerebral
agent
Prior art date
Application number
PCT/JP2008/000306
Other languages
English (en)
French (fr)
Inventor
Nobuo Sasaki
Yuichi Tei
Ryosuke Echigo
Shigeki Suzuki
Touru Hakukawa
Original Assignee
Next21 K.K.
The University Of Tokyo
Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Next21 K.K., The University Of Tokyo, Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo filed Critical Next21 K.K.
Priority to JP2009500094A priority Critical patent/JP5781727B2/ja
Priority to CN2008800057587A priority patent/CN101646442B/zh
Priority to EP08710459.2A priority patent/EP2198869B1/en
Priority to US12/528,116 priority patent/US8283337B2/en
Publication of WO2008102563A1 publication Critical patent/WO2008102563A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

　【課題】　本発明は，血管攣縮の治療剤又は予防剤を提供することを目的とする。本発明は，脳血管攣縮の治療剤又は予防剤のみならず，動脈の血管攣縮の治療剤又は予防剤をも提供することを目的とする。また本発明は，脳虚血症及び脳梗塞の治療剤又は予防剤を提供することを目的とする。 　【解決手段】　上記課題は，トレハロースを有効成分として含有する血管攣縮，脳虚血症，又は脳梗塞の治療剤又は予防剤などにより解決される。トレハロースを含有した薬剤を用いることで，血管が狭小化する現象や内膜や中膜が肥大化する現象を抑えることができ,血管攣縮及び血管攣縮に関連する疾患を予防又は治療することができる。 　
PCT/JP2008/000306 2007-02-23 2008-02-22 血管攣縮の治療剤又は予防剤 WO2008102563A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009500094A JP5781727B2 (ja) 2007-02-23 2008-02-22 血管攣縮の治療剤又は予防剤
CN2008800057587A CN101646442B (zh) 2007-02-23 2008-02-22 血管痉挛的治疗剂或预防剂
EP08710459.2A EP2198869B1 (en) 2007-02-23 2008-02-22 Trehalose for the treatment or prevention of vasospasm
US12/528,116 US8283337B2 (en) 2007-02-23 2008-02-22 Therapeutic or prophylactic agent for vasoconstriction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-044744 2007-02-23
JP2007044744 2007-02-23

Publications (1)

Publication Number Publication Date
WO2008102563A1 true WO2008102563A1 (ja) 2008-08-28

Family

ID=39709843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/000306 WO2008102563A1 (ja) 2007-02-23 2008-02-22 血管攣縮の治療剤又は予防剤

Country Status (5)

Country Link
US (1) US8283337B2 (ja)
EP (1) EP2198869B1 (ja)
JP (1) JP5781727B2 (ja)
CN (1) CN101646442B (ja)
WO (1) WO2008102563A1 (ja)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2214714A4 (en) * 2007-10-31 2011-01-12 Diffusion Pharmaceuticals Llc NEW CLASS OF THERAPEUTIC AGENTS THAT ENHANCE SMALL MOLECULE DELIVERY
CN102395548A (zh) * 2009-04-15 2012-03-28 奥斯金生医公司 全氟化碳类乳液
JP2012509870A (ja) * 2008-11-25 2012-04-26 オキシジェン・バイオセラピューティクス・インコーポレイティド ペルフルオロカーボンゲル製剤
US8901174B2 (en) 2007-04-13 2014-12-02 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
US8974822B2 (en) 2010-06-02 2015-03-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
US9604899B2 (en) 2002-02-25 2017-03-28 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US9950067B2 (en) 2005-02-24 2018-04-24 Diffusion Pharmaceuticals, LLC Trans carotenoids, their synthesis, formulation and uses
US10130689B2 (en) 2009-06-22 2018-11-20 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
US11185523B2 (en) 2016-03-24 2021-11-30 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2861300A4 (en) * 2012-06-13 2016-03-16 David W Newell TREATMENT OF SUBARACHOIDAL HEMATOMES USING SONOTHROMBOLYSIS AND RELATED DEVICES, SYSTEMS AND METHODS
KR20160009617A (ko) * 2013-05-07 2016-01-26 바이오 블라스트 파마 리미티드 트레할로스의 비경구 투여에 의한 단백질 응집 근병증 및 신경퇴행성 질환의 치료
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
ITCT20130013A1 (it) * 2013-06-06 2014-12-07 Domuspharma Srl Trealosio come colon protettore e catalizzatore intestinale
ES2534708B1 (es) * 2013-10-25 2015-12-17 Universidad De Sevilla Composiciones y preparaciones combinadas para el tratamiento del vasoespasmo arterial
EP3411043A4 (en) * 2016-02-01 2019-10-02 Razani, Babak COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROSIS, HEPATATATATOSIS AND OTHER RELATED DISEASES
CN115103699A (zh) * 2020-02-08 2022-09-23 西尔维安公司 用于治疗和预防血管痉挛的医疗设备、治疗方法和诊断方法

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5640610A (en) 1979-09-12 1981-04-16 Akira Endo Remedy for hyperlipemia containing metal salt of monacolin k as the major component
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS6113699B2 (ja) 1980-06-06 1986-04-15 Sankyo Kk
JPS61227581A (ja) 1985-04-02 1986-10-09 Asahi Chem Ind Co Ltd 血管拡張剤
US4678783A (en) 1983-11-04 1987-07-07 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
JPS641476B2 (ja) 1980-02-04 1989-01-11 Merck & Co Inc
JPH06116166A (ja) 1992-10-08 1994-04-26 Shiseido Co Ltd 脳血管攣縮予防または治療剤
JPH0789876A (ja) * 1993-09-20 1995-04-04 Shiseido Co Ltd 徐放性製剤
JPH07173072A (ja) 1993-12-17 1995-07-11 Shiseido Co Ltd 脳血管攣縮抑制剤
JPH07267880A (ja) 1994-02-14 1995-10-17 Shiseido Co Ltd 徐放化脳血管攣縮抑制剤
JPH0826994A (ja) 1994-07-22 1996-01-30 Eisai Co Ltd 脳血管攣縮治療剤
JPH0925239A (ja) 1995-07-14 1997-01-28 Mochida Pharmaceut Co Ltd 脳血管攣縮治療剤
JPH10505319A (ja) 1994-05-13 1998-05-26 シンセティック ブラッド インターナショナル インコーポレーテッド 肺に障害を持つ哺乳動物の通常の呼吸を補助する方法
JP2774035B2 (ja) 1992-12-04 1998-07-09 鐘紡株式会社 美白化粧料
JPH11171778A (ja) 1997-12-09 1999-06-29 Hayashibara Biochem Lab Inc 血行改善剤
JPH11507351A (ja) * 1995-06-07 1999-06-29 アライアンス ファーマシューティカル コーポレイション 血管酸化窒素リザーバーとしての液体フルオロカーボンエマルジョン
JPH11222439A (ja) 1998-02-03 1999-08-17 Dainippon Pharmaceut Co Ltd 脳血管攣縮抑制薬
JP2962731B2 (ja) 1986-11-10 1999-10-12 バイオピュアー、コーポレーション 超純枠半合成代用血液
JP2000086518A (ja) 1998-09-10 2000-03-28 Mitsubishi Chemicals Corp 血管攣縮の予防・治療剤
JP2000191540A (ja) * 1998-12-29 2000-07-11 Rakaro Biopharmaceutical Inc 再狭窄薬物療法
JP2000247904A (ja) 1999-02-25 2000-09-12 Chemo Sero Therapeut Res Inst 脳血管攣縮治療剤および血腫除去剤
JP2000516569A (ja) 1995-12-01 2000-12-12 シンセティック・ブラッド・インターナショナル・インコーポレイテッド 生物学的ガス交換用改良ペルフルオロカーボン及び使用方法
JP2002161049A (ja) 2000-11-28 2002-06-04 Terumo Corp 血管内膜肥厚抑制剤
JP2003503353A (ja) 1999-06-29 2003-01-28 オリオン コーポレーション 冠状動脈移植片血管攣縮の治療または予防方法
JP2003522094A (ja) 1997-11-20 2003-07-22 シンセティック・ブラッド・インターナショナル・インコーポレイテッド 液体換気及び人工血液のための選択されたｃ１０パーフルオロ炭化水素
JP2004536368A (ja) 2001-01-16 2004-12-02 ボード オブ レジェンツ，ザ ユニバーシティー オブ テキサス システム 天然状態のアンサンブルにおけるアミノ酸の熱力学的傾向：折りたたみ認識に関する関係
WO2005037236A2 (en) * 2003-10-17 2005-04-28 Arizona Board Of Regents Novel heat shock protein 20-related polypeptides and uses therefor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950007873A (ko) * 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
EP0868916A3 (en) * 1997-03-04 2004-09-15 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Reduction inhibitory agent for active-oxygen eliminating activity
JP4203159B2 (ja) * 1997-12-09 2008-12-24 株式会社林原生物化学研究所 神経機能調節剤
WO2001060388A1 (fr) * 2000-02-15 2001-08-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Activateur de cellules
JP2001302517A (ja) * 2000-04-24 2001-10-31 Tokyo Univ Of Pharmacy & Life Science 脳浮腫の予防治療薬
GB0024271D0 (en) * 2000-09-25 2000-11-15 Colaco Camilo Improved methods and compositions for pulmonary delivery of actives
JP4754066B2 (ja) * 2000-12-22 2011-08-24 株式会社林原生物化学研究所 抗関節障害剤
CN1761450B (zh) * 2003-02-13 2010-05-05 株式会社林原生物化学研究所 特征在于含有α,α-海藻糖的糖类衍生物的皮肤外用剂
EP1652527A4 (en) * 2003-07-18 2012-03-14 Hayashibara Biochem Lab MINERAL ABSORBENT AND ITS USE
US20050181044A1 (en) * 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements, green coffee extract
WO2005087182A1 (ja) * 2004-03-17 2005-09-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo 機能性粉体
MY142987A (en) * 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention
JP2006342108A (ja) * 2005-06-09 2006-12-21 Mitsubishi Chemicals Corp アミロスフェロイドにより発生する疾患の予防治療剤
WO2007035583A1 (en) * 2005-09-19 2007-03-29 University Of Maryland, Baltimore Lyophilization of hemoglobin solutions
US20070167396A1 (en) * 2006-01-19 2007-07-19 Solazyme, Inc. Methods and compositions for cholesterol reduction in mammals
CA2703946A1 (en) * 2007-10-31 2009-05-07 Diffusion Pharmaceuticals Llc A new class of therapeutics that enhance small molecule diffusion

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5640610A (en) 1979-09-12 1981-04-16 Akira Endo Remedy for hyperlipemia containing metal salt of monacolin k as the major component
JPS641476B2 (ja) 1980-02-04 1989-01-11 Merck & Co Inc
JPS6113699B2 (ja) 1980-06-06 1986-04-15 Sankyo Kk
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4678783A (en) 1983-11-04 1987-07-07 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
JPS61227581A (ja) 1985-04-02 1986-10-09 Asahi Chem Ind Co Ltd 血管拡張剤
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
JPH0757751B2 (ja) 1986-05-30 1995-06-21 ワ−ナ−−ランバ−ト・コンパニ− トランス−６−〔２−（３−または４−カルボキサミド置換ピロ−ル−１−イル）アルキル〕−４−ヒドロキシピラン−２−オン
JP2962731B2 (ja) 1986-11-10 1999-10-12 バイオピュアー、コーポレーション 超純枠半合成代用血液
JPH06116166A (ja) 1992-10-08 1994-04-26 Shiseido Co Ltd 脳血管攣縮予防または治療剤
JP2774035B2 (ja) 1992-12-04 1998-07-09 鐘紡株式会社 美白化粧料
JPH0789876A (ja) * 1993-09-20 1995-04-04 Shiseido Co Ltd 徐放性製剤
JPH07173072A (ja) 1993-12-17 1995-07-11 Shiseido Co Ltd 脳血管攣縮抑制剤
JPH07267880A (ja) 1994-02-14 1995-10-17 Shiseido Co Ltd 徐放化脳血管攣縮抑制剤
JPH10505319A (ja) 1994-05-13 1998-05-26 シンセティック ブラッド インターナショナル インコーポレーテッド 肺に障害を持つ哺乳動物の通常の呼吸を補助する方法
JPH0826994A (ja) 1994-07-22 1996-01-30 Eisai Co Ltd 脳血管攣縮治療剤
JPH11507351A (ja) * 1995-06-07 1999-06-29 アライアンス ファーマシューティカル コーポレイション 血管酸化窒素リザーバーとしての液体フルオロカーボンエマルジョン
JPH0925239A (ja) 1995-07-14 1997-01-28 Mochida Pharmaceut Co Ltd 脳血管攣縮治療剤
JP2000516569A (ja) 1995-12-01 2000-12-12 シンセティック・ブラッド・インターナショナル・インコーポレイテッド 生物学的ガス交換用改良ペルフルオロカーボン及び使用方法
JP2003522094A (ja) 1997-11-20 2003-07-22 シンセティック・ブラッド・インターナショナル・インコーポレイテッド 液体換気及び人工血液のための選択されたｃ１０パーフルオロ炭化水素
JPH11171778A (ja) 1997-12-09 1999-06-29 Hayashibara Biochem Lab Inc 血行改善剤
JPH11222439A (ja) 1998-02-03 1999-08-17 Dainippon Pharmaceut Co Ltd 脳血管攣縮抑制薬
JP2000086518A (ja) 1998-09-10 2000-03-28 Mitsubishi Chemicals Corp 血管攣縮の予防・治療剤
JP2000191540A (ja) * 1998-12-29 2000-07-11 Rakaro Biopharmaceutical Inc 再狭窄薬物療法
JP2000247904A (ja) 1999-02-25 2000-09-12 Chemo Sero Therapeut Res Inst 脳血管攣縮治療剤および血腫除去剤
JP2003503353A (ja) 1999-06-29 2003-01-28 オリオン コーポレーション 冠状動脈移植片血管攣縮の治療または予防方法
JP2002161049A (ja) 2000-11-28 2002-06-04 Terumo Corp 血管内膜肥厚抑制剤
JP2004536368A (ja) 2001-01-16 2004-12-02 ボード オブ レジェンツ，ザ ユニバーシティー オブ テキサス システム 天然状態のアンサンブルにおけるアミノ酸の熱力学的傾向：折りたたみ認識に関する関係
WO2005037236A2 (en) * 2003-10-17 2005-04-28 Arizona Board Of Regents Novel heat shock protein 20-related polypeptides and uses therefor

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
"Development of endothelin receptor antagonist- converting enzyme inhibitors", BIOMEDICINE & THERAPEUTICS, August 2004 (2004-08-01)
BIOPHYS. J., vol. 89, 2005, pages 4111 - 4121
CHEN F. ET AL.: "Development of new organ preservation solution (ET-Kyoto solution)", ORGAN. BIOL., vol. 12, no. 1, 2005, pages 9 - 20, XP008120358 *
ECHIGO R. ET AL.: "Rat Daigae Domyaku Model o Mochiita Trehalose ni yoru Kekkan Renshuku no Yokusei Koka", ANNUAL MEETING OF THE JAPAN NEUROSURGICAL SOCIETY ABSTRACT (CD-ROM), 2007, pages ABSTR. NO. 2K-P30-7-9, XP008112529 *
FRIZZELL RT ET AL.: "Screening for ocular hemorrhages in patients with ruptured cerebral aneurysms: a prospective study of 99 patients", NEUROSURGERY, vol. 41, no. 3, pages 529 - 533
KUREISHI: "The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animal.", NATURE MED., vol. 200, no. 6, pages 1004 - 1010
LEVITSKY J. ET AL.: "Sodium Ion/Hydrogen Ion Exchange Inhibition: A New Pharmacologic Approach to Myocardial Ischemia and Reperfusion Injury", J. CLIN. PHARMACOL., vol. 38, no. 10, 1998, pages 887 - 897, XP000920868 *
MAYBERG M.C. ET AL.: "Guidelines for the Management of Aneurysmal Subarachnoid Homorrhage. A Statement for Healthcare Professionals From a Special Writing Group for Stroke Council", AMERICAN HEART ASSOCIATION CIRCULATION, vol. 90, no. 5, 1994, pages 2592 - 2605, XP008112474 *
MAYBERG, M. R. ET AL.: "Guidelines for the Management of Aneurismal subarachnoid Hemorrhage", CIRCULATION, vol. 90, no. 5, 1994, pages 2592 - 2605
MAYBERG, M. R. ET AL.: "Guidelines for the Management of Aneurismal subarachnoid Hemorrhage", CIRCULATION., vol. 90, no. 5, 1994, pages 2592 - 2605
MAYBERG, M. R. ET AL.: "Guidelines for the ManagementofAneurismalsubarachnoid Hemorrhage", CIRCULATION., vol. 90, no. 5, 1994, pages 2592 - 2605
MINORU KUROKI ET AL., EFFECT OF VASOSPASM ON HEME OXYGENASES IN RAT MODEL OF SUBARACHNOID HEMORRHAGE
NAKAMURA ET AL., JAPAN NEUROSURGICAL SOCIETY, ABSTRACT OF 49TH ANNUAL MEETING, vol. 199, 1990
NAKANE H.: "Nokekkan Shogai to Sanka Stress", MOLECULAR CARDIOVASCULAR MEDICINE, vol. 3, no. 4, 2002, pages 455 - 462, XP008115694 *
R. LOCH: "A Review of Hemoglobin and the Pathogenesis of Cerebral Vasospasm", STROKE, vol. 22, no. 8, 1991, pages 971 - 982
SHIBUYA, J. NEUROSURG., vol. 76, 1992, pages 571 - 577
TAHARA S. ET AL.: "Junkanki Shikkan to Rho Kinase", CIRCULATION CONTROL, vol. 27, no. 2, 2006, pages 121 - 129, XP008115695 *
TANAKA H. ET AL.: "Hikinuki Sonsho Kekkan ni Okeru Reperfusion Injury to Setchaku Inshi (ICAM-1) no Hatsugen ni Tsuite", DAI 26 KAI NIPPON MICROSURGERY GAKUJUTSU SHUKAI SHOROKU, 2000, pages 186 + ABSTR. NO. 181, XP003021983 *
YADA T.: "Bisho Junkan ni Okeru Naihi Izonsei Ketsuryu Chosetsu Inshi no Yakuwari", KESSEN SHIKETSUSHI, vol. 16, no. 4, 2005, pages 425 - 428, XP003021972 *
YAMAZAKI K. ET AL.: "Kyoketsu Saikanryu Shogai ni Chakumoku shita Shinkin Hogoho to Shinkin Hogoeki no kento", JOURNAL OF JAPAN SURGICAL SOCIETY, vol. 105, 2004, pages 566 + ABSTR. NO. PS-147-2, XP008112522 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9604899B2 (en) 2002-02-25 2017-03-28 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US11278621B2 (en) 2005-02-24 2022-03-22 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
US9950067B2 (en) 2005-02-24 2018-04-24 Diffusion Pharmaceuticals, LLC Trans carotenoids, their synthesis, formulation and uses
US8901174B2 (en) 2007-04-13 2014-12-02 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
EP2214714A4 (en) * 2007-10-31 2011-01-12 Diffusion Pharmaceuticals Llc NEW CLASS OF THERAPEUTIC AGENTS THAT ENHANCE SMALL MOLECULE DELIVERY
JP2012509870A (ja) * 2008-11-25 2012-04-26 オキシジェン・バイオセラピューティクス・インコーポレイティド ペルフルオロカーボンゲル製剤
CN102395548A (zh) * 2009-04-15 2012-03-28 奥斯金生医公司 全氟化碳类乳液
US10130689B2 (en) 2009-06-22 2018-11-20 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
US11147859B2 (en) 2009-06-22 2021-10-19 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
US8974822B2 (en) 2010-06-02 2015-03-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
US10016384B2 (en) 2010-06-02 2018-07-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
US11491129B2 (en) 2010-06-02 2022-11-08 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
US11185523B2 (en) 2016-03-24 2021-11-30 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer

Also Published As

Publication number Publication date
JP5781727B2 (ja) 2015-09-24
EP2198869A1 (en) 2010-06-23
CN101646442A (zh) 2010-02-10
US8283337B2 (en) 2012-10-09
CN101646442B (zh) 2013-09-04
JPWO2008102563A1 (ja) 2010-05-27
US20100035837A1 (en) 2010-02-11
EP2198869B1 (en) 2015-09-16
EP2198869A4 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
WO2008102563A1 (ja) 血管攣縮の治療剤又は予防剤
WO2011061330A3 (de) Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
WO2010030728A3 (en) Devices and systems for delivery of therapeutic agents to body lumens
WO2013063120A3 (en) Nmda receptor modulators and uses thereof
ZA200900788B (en) Manufacture,method,and use of active substance-releasing medical products for permanently keeping blood vessels open
UA98629C2 (ru) Соединения и способ модуляции киназ
WO2011049958A3 (en) Modulation of gel temperature of poloxamer-containing formulations
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2011050206A3 (en) Compositions and methods for the treatment of sinonasal disorders
WO2007025613A3 (en) Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
WO2010135530A3 (en) Compounds, compositions and methods for modulating uric acid levels
WO2009065596A3 (en) Use of mnk inhibitors for the treatment of alzheimer's disease
IL201479A0 (en) Titration of tapentadol
WO2009025926A3 (en) Nanoparticle-coated medical devices and formulations for treating vascular disease
WO2012046030A3 (en) Phosphodiesterase inhibitors
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2011109570A3 (en) Therapeutic delivery devices, systems, and methods
ZA201305994B (en) Use of n-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptortor activity
WO2009127973A3 (en) Introducer
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
WO2009134079A3 (ko) 약제학적 제제
WO2009045543A8 (en) Treatment of conditions related to shock
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
ZA201109415B (en) Re-establishment of blood flow in blocked human arteries by transferring nano-encapsulated drug through medical devices,designed for the same and releasing the nano-encapsulated drug in human artery with body ph

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880005758.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08710459

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009500094

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12528116

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008710459

Country of ref document: EP